Volume Spike Investor

Human Genome Sciences, Inc. (NASDAQ: HGSI) is soaring after its expected study results showed that its second round of Phase II data showed that the Benlysta lupus drug was very effective at higher doses.  The lower doses did not show as much improvement, although this is due to the notion that there have been no real lupus treatments in years and years.  At 8:30 AM EST we have seen 2.2 million shares trade hands and the stock is trading up 34% at $25.10.  This will mark new 52-week highs and highs not seen since 2002 or 2003.

JON C. OGG